Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Inclusion Criteria:

1. Written informed consent signed by the participant, obtained before anystudy-related assessment is performed

2. At least 18 years of age at the time of signing the informed consent form (ICF)

3. Completed the EoT or EoS Visit (as applicable) in a lorundrostat study with theoption of transitioning to the OLE study, in accordance with the parent studyprotocol

4. Fertile male subjects and female subjects of childbearing potential, and theirpartners, must agree to use an acceptable method of contraception from study entryto 28 days after the last dose of study drug

5. Willing and able to comply with the study instructions and attend all scheduledstudy visits

[Randomized treatment withdrawal substudy only]

6. Written informed consent to participate in the RTW substudy signed by theparticipant, obtained before any RTW study-related assessment is performed

Exclusion Criteria:

1. Women who are pregnant, plan to become pregnant, or are breast-feeding

2. Use, or anticipated use during the course of the study, of a prohibited medicationas listed in Section 6.7.1 of the protocol

3. In the opinion of the Investigator, any condition that will preclude participationin the study

[Randomized treatment withdrawal substudy only]

4. Non-compliance with study medication(s) (defined as taking <75% or >125% of thestudy drug provided) during the first 12 weeks of MLS-101-901